| |
SEC
FILE NUMBER
001-39318 |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
| (Check one): |
☐
Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR |
| |
|
| |
For Period Ended: September 30, 2026 |
| |
|
| |
☐
Transition Report on Form 10-K |
| |
☐
Transition Report on Form 20-F |
| |
☐
Transition Report on Form 11-K |
| |
☐
Transition Report on Form 10-Q |
| |
|
| |
For the Transition Period Ended: |
|
| Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein. |
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I – REGISTRANT INFORMATION
LANTERN
PHARMA INC.
Full
Name of Registrant
Not
applicable
Former
Name if Applicable
1920
McKinney Avenue, 7th Floor
Address
of Principal Executive Office (Street and Number)
Dallas,
Texas 75201
City,
State and Zip Code
PART
II – RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if appropriate)
| ☒
|
(a) |
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| (b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
| (c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART
III – NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not
be filed within the prescribed time period.
Lantern
Pharma Inc. (the “Company,” “we,” or “our”) has determined that it is unable to file, without unreasonable
effort or expense, its Quarterly Report on Form 10-Q for the three months ended September 30, 2026 (the “Form 10-Q”) by November
16, 2026, the prescribed due date for such filing. This delay principally relates to changes in senior executive management and technical
accounting matters in connection with the Company’s proposed settlement of a claim. The Company does not expect any material changes
or adjustments to previously published financial results.
The
Company expects to file the Form 10-Q within the five-calendar day extension period as provided by Rule 12b-25 under the Securities Exchange
Act of 1934, as amended.
PART
IV – OTHER INFORMATION
| (1) | Name and telephone
number of person to contact in regard to this notification. |
| David Margrave |
|
(972) |
|
277-1136 |
| (Name) |
|
(Area Code) |
|
(Telephone Number) |
| (2) | Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange
Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months
or for such shorter period that the registrant was required to file such report(s) been filed?
If answer is no, identify report(s). |
Yes
☒ No ☐
| (3) | Is
it anticipated that any significant change in results of operations from the corresponding
period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof? |
Yes ☐ No ☒
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why
a reasonable estimate of the results cannot be made.
Lantern
Pharma Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 17, 2026 |
By: |
/s/
David Margave |
| |
|
Name: |
David
Margrave |
| |
|
Title: |
Chief Executive Officer and Chief Financial Officer
|